**Supplementary Table 3. Lung function tests with increasing FIB-4 quartiles in men and women with MAFLD**

|  |  |  |
| --- | --- | --- |
|  | FIB-4 quartile |  |
| MAFLD (men, *n*=299) | Quartile 1 (0–0.36, *n*=75), mean±SD | Quartile 2 (0.37–0.47, *n*=74), mean±SD | Quartile 3 (0.48–0.62, *n*=76), mean±SD | Quartile 4 (0.63–3.91, *n*=74), mean±SD | *p* |
| Lung function test |  |  |  |  |  |
| FVC, L | 3.26±0.71 | 3.16±0.82 | 3.01±0.70 | 2.72±0.73 | <0.001 |
| FVC, % of predicted value | 92.90±16.13 | 91.24±16.64 | 90.72±17.41 | 84.80±16.21 | 0.017 |
| FEV1, L | 2.53±0.70 | 2.50±0.62 | 2.37±0.64 | 2.07±0.63 | <0.001 |
| FEV1, % of predicted value | 80.12±12.16 | 79.14±16.43 | 78.29±16.63 | 71.72±19.82 | 0.007 |
| FEV1/FVC, % | 79.10±7.41 | 78.94±10.24 | 77.46±8.16 | 76.89±12.99 | 0.464 |
| MAFLD (women, *n*=220) | Quartile 1(0-0.38, n=54) | Quartile 2(0.38-0.53, n=55) | Quartile 3(0.54-0.71, n=55) | Quartile 4(0.71-1.86, n=56) | P |
| Lung function test |  |  |  |  |  |
| FVC, L | 2.27±0.82 | 1.92±0.83 | 1.91±0.82 | 1.89±0.69 | <0.001 |
| FVC, % of predicted value | 88.14±17.48 | 87.37±17.56 | 85.37±15.67 | 83.18±16.93 | 0.433 |
| FEV1, L | 1.85±0.46 | 1.63±0.31 | 1.58±0.40 | 1.55±0.37 | **<0.001** |
| FVC, % of predicted value | 84.54±16.55 | 83.09±15.56 | 83.06±17.79 | 81.09±17.17 | 0.722 |
| FEV1/FVC, % | 85.52±8.49 | 82.95±9.45 | 82.18±10.46 | 81.86±8.62 | 0.339 |

\*One-way analysis of variance. FIB-4, fibrosis 4 score; FVC= forced vital capacity; FEV1, forced expiratory volume measured in the first second of exhalation; NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic dysfunction-associated fatty liver disease; non-MD-NAFLD, nonmetabolic dysfunction-NAFLD.